Who are CP-690,550 Ointment 1's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Litfulo, Tofacitinib plus mesalamine, Tofacitinib with methotrexate, Tofacitinib (Xeljanz), Ritlecitinib 20 mg, JAK Inhibitor.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/cp-690-550-ointment-1.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

CP-690,550 Ointment 1 — Competitive Intelligence Brief

CP-690,550 Ointment 1 (CP-690,550 Ointment 1) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: JAK inhibitor. Area: Immunology.

phase 2 JAK inhibitor JAK3 Immunology Small molecule Live · refreshed every 30 min

Target snapshot

CP-690,550 Ointment 1 (CP-690,550 Ointment 1) — Pfizer. CP-690,550 is a Janus kinase (JAK) inhibitor.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
CP-690,550 Ointment 1 TARGET	CP-690,550 Ointment 1	Pfizer	phase 2	JAK inhibitor	JAK3
Litfulo	Ritlecitinib Tosylate	Pfizer	marketed	Kinase inhibitor	Janus kinase 3 (JAK3) and tyrosine kinase expressed in hepatocellular carcinoma (TEC) kinase family	2023-01-01
Tofacitinib plus mesalamine	Tofacitinib plus mesalamine	Post Graduate Institute of Medical Education and Research, Chandigarh	marketed	JAK inhibitor plus aminosalicylate	JAK1/JAK3 (tofacitinib); unclear specific target for mesalamine (likely prostaglandin-related)
Tofacitinib with methotrexate	Tofacitinib with methotrexate	Pfizer	marketed	JAK inhibitor + DMARD	JAK1, JAK3 (tofacitinib); dihydrofolate reductase (methotrexate)
Tofacitinib (Xeljanz)	tofacitinib-xeljanz	Pfizer	marketed	Janus Kinase Inhibitor	JAK1 and JAK3
Ritlecitinib 20 mg	ritlecitinib-20-mg	Pfizer	marketed	small molecule inhibitor	JAK3/STAT3 pathway
JAK Inhibitor	JAK Inhibitor	Fred Hutchinson Cancer Center	marketed	JAK inhibitor	JAK1, JAK2, JAK3, and/or TYK2

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (JAK inhibitor class)

Pfizer · 19 drugs in this class
Aclaris Therapeutics, Inc. · 2 drugs in this class
Beijing Friendship Hospital · 2 drugs in this class
Azienda Ospedaliero, Universitaria Pisana · 1 drug in this class
CAGE Bio Inc. · 1 drug in this class
CTI BioPharma · 1 drug in this class
Celgene · 1 drug in this class
Fred Hutchinson Cancer Center · 1 drug in this class
LEO Pharma · 1 drug in this class
McMaster University · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). CP-690,550 Ointment 1 — Competitive Intelligence Brief. https://druglandscape.com/ci/cp-690-550-ointment-1. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab